Literature DB >> 27690175

Risk of Hematologic Malignancies in the Offspring of Female Workers of the Mayak Nuclear Facility in the Southern Urals, Russian Federation.

I Deltour1, Y Tsareva2, S J Schonfeld1, V V Vostrotin2, P Okatenko2, M Sokolnikov2, J Schüz1.   

Abstract

Long-term effects of in utero exposure to ionizing radiation remain poorly quantified in humans. In this study, the risk of hematologic malignancies was investigated in offspring of female workers of the Mayak Production Association, a large Russian nuclear facility. Excess relative risks (ERR) for exposure to gamma radiation and plutonium were estimated in a cohort of 8,466 offspring who were born between January 1, 1948 and December 31, 1988 and followed until 2009. An unstable linear ERR of 1.12 (95% CI 0.11-3.44) per 100 mGy gamma exposure in utero was estimated based on 32 incident hematologic malignancies in 277,002 person-years under risk. The ERR was increased in the dose category 20-79 mGy gamma exposure in utero (1.75, 95% CI 0.04; 5.63), while the other dose categories showed decreased or unstable estimates. Leukemia showed an ERR of 1.76 (95% CI 0.01-8.33) per 100 mGy based on 13 cases. There was no consistent association with plutonium exposure. While an increased risk of hematologic malignancies after gamma exposure in utero was suggested, the small numbers prevented more definitive conclusions.

Entities:  

Mesh:

Year:  2016        PMID: 27690175     DOI: 10.1667/RR14399.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  2 in total

1.  In utero exposure to radiation and haematological malignancies: pooled analysis of Southern Urals cohorts.

Authors:  Joachim Schüz; Isabelle Deltour; Lyudmila Y Krestinina; Yulia V Tsareva; Evgenia I Tolstykh; Mikhail E Sokolnikov; Alexander V Akleyev
Journal:  Br J Cancer       Date:  2016-11-17       Impact factor: 7.640

Review 2.  Health Impacts of Low-Dose Ionizing Radiation: Current Scientific Debates and Regulatory Issues.

Authors:  Alexander Vaiserman; Alexander Koliada; Oksana Zabuga; Yehoshua Socol
Journal:  Dose Response       Date:  2018-09-19       Impact factor: 2.658

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.